Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Welsh

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Scientific Reports|October 18, 2017
Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activityCarolyn J Loveridge, Rob J van 't Hof, Gemma Charlesworth, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
Neuro-Oncology Practice|May 15, 2023
Lifestyle coaching is feasible in fatigued brain tumor patients: A phase I/feasibility, multi-center, mixed-methods randomized controlled trialAlasdair G Rooney, William Hewins, Amie Walker, et al.
British Journal of Cancer|June 23, 2022
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)Grant D Stewart, Sarah J Welsh, Stephan Ursprung, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Scientific Reports|October 18, 2017
Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activityCarolyn J Loveridge, Rob J van 't Hof, Gemma Charlesworth, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
Neuro-Oncology Practice|May 15, 2023
Lifestyle coaching is feasible in fatigued brain tumor patients: A phase I/feasibility, multi-center, mixed-methods randomized controlled trialAlasdair G Rooney, William Hewins, Amie Walker, et al.
British Journal of Cancer|June 23, 2022
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)Grant D Stewart, Sarah J Welsh, Stephan Ursprung, et al.
Pageof 3